Hologic, Inc. (HOLX)

Over the past six months, Hologic's stock price has experienced various influences and has risen 13.92%. In Q4 2025, Hologic reported adjusted EPS of $1.13 and revenue of $1.05 billion, exceeding expectations. Several investment firms downgraded Hologic's stock between October 2025 and January 2026. Reports emerged in late 2025 and early January 2026 that private equity firms Blackstone and TPG were in advanced stages of acquiring Hologic at $79 per share. In Q3 2025, Hologic reported total revenue of $1.024 billion, a slight growth of 0.4% year-over-year, exceeding guidance.

While specific monthly seasonality data for HOLX is not readily available, some insights into demand patterns can be inferred. A significant portion of Hologic's revenue comes from consumables, suggesting a degree of stability in demand. The company experienced abnormal organic growth during the global pandemic, followed by a normalization of its business in the post-pandemic period. The Breast Health segment experienced a decline in product revenues in Q2 2025, attributed to lower demand for digital mammography systems, indicating that capital equipment sales can be subject to fluctuations. The company's molecular business, with Panther instruments primarily on rental agreements, typically involves three to five-year contracts with fixed pricing, contributing to predictable revenue streams.

Hologic, Inc. is a global medical technology company focused on improving women's health through early detection and treatment, operating in the Healthcare sector under the Medical Instruments & Supplies or Medical Electronics industry. The company's business is structured around four main segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Key products include Aptima molecular diagnostic assays, ThinPrep System, Rapid Fetal Fibronectin Test, solutions for breast imaging and biopsy, MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, CoolSeal vessel sealing portfolio, JustRight surgical stapler, Horizon DXA, and Fluoroscan Insight FD mini C-arm.

Hologic has a significant global presence, serving healthcare providers and patients in over 130 countries. The United States is its largest market, accounting for approximately 69% of the firm's revenue. Europe contributes about 20% of total sales, while Asia accounts for 8%, and other international markets make up the remaining 3%.

Hologic maintains a strong brand reputation as a global leader in women's health, dedicated to advancing lives through innovative diagnostic, medical imaging, and surgical products. The company has been recognized in various Forbes lists, including "America's Best-In-State Companies (2026)", "World's Best Employers (2025)", and "America's Best Employers For Company Culture (2025)".

Hologic's ownership structure is predominantly institutional, with approximately 79.30% to 94.73% of the company's stock held by institutional investors. Insiders own about 1.43% to 1.51%, and public/individual investors (retail) hold around 19.27% to 32.55%. Major institutional owners include Vanguard Group Inc, T. Rowe Price Investment Management, Inc., and BlackRock, Inc. The largest individual shareholder is Carl C. Icahn, owning 28.15 million shares, representing 12.63% of the company.